Respiratory syncytial virus in hematopoietic cell transplant recipients: Factors determining progression to lower respiratory tract disease

Journal of Infectious Diseases

Volumn 209, Issue 8, 2014, Pages 1151-1152

  Ljungman, Per ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ribavirin; RSV; stem cell transplantation

Indexed keywords

IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RIBAVIRIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; LOWER RESPIRATORY TRACT; LOWER RESPIRATORY TRACT DISEASE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; NOTE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; SMOKING; VIRUS LOAD; WHOLE BODY RADIATION;

RIBAVIRIN; RSV; STEM CELL TRANSPLANTATION;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT DISEASES;

EID: 84897452143     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit833     Document Type: Note

References (17)

1. Englund J, Sullivan C, Jordan M, Dehner L, Vercelotti G, Balfour H. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988; 109:203-8.
2. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165:987-93.
3. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22:778-82.
4. Kim Y-J, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: Factors determining progression to lower respiratory tract disease. J Infect Dis 2014; 209: 1195-204.
5. Anaissie EJ, Mahfouz TH, Aslan T, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: Implications for management. Blood 2004; 103:1611-7.
6. Ljungman P,Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: A prospective study from the Infectious DiseasesWorking Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28:479-84.
7. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: Singlecenter study and review of the literature. Clin Infect Dis 2008; 46:402-12.
8. Lehners N, Schnitzler P, Geis S, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant 2013; 48:1548-53.
9. Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11:781-96.
10. Modestou MA, Manzel LJ, El-Mahdy S, Look DC. Inhibition of IFN-gamma-dependent antiviral airway epithelial defense by cigarette smoke. Respir Res 2010; 11:64.
11. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44:245-9.
12. Garcia R, Raad I, Abi-Said D, et al. Nosocomial respiratory syncytial virus infection: Prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol 1997; 18:412-6.
13. Chemaly RF, Torres HA, Munsell MF, et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 2012; 206:1367-71.
14. Ghosh S, Champlin RE, Englund J, et al. Respiratorysyncytial virusupper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000; 25:751-5.
15. Nichols WG, Gooley T, Boeckh M. Community-Acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: The Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 (Suppl):11S-5S.
16. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013; 68:1872-80.
17. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117: 2755-63.